Reactive oxygen species promote ovarian cancer progression via the HIF-1α/LOX/E-cadherin pathway

Oncology Reports

Volumn 32, Issue 5, 2014, Pages 2150-2158

  Wang, Yu ^a   Ma, Jun ^a   Shen, Haoran ^a   Wang, Chengjie ^a   Sun, Yueping ^b   Howell, Stephen B ^c   Lin, Xinjian ^c  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

E cadherin; Hypoxia inducible transcription factor 1; Lysyl oxidase; Ovarian carcinomas; Reactive oxygen species

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1ALPHA; PROTEIN LYSINE 6 OXIDASE; REACTIVE OXYGEN METABOLITE; UVOMORULIN; CADHERIN; CDH1 PROTEIN, HUMAN; HIF1A PROTEIN, HUMAN;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL; CANCER GROWTH; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CARCINOGENICITY; CELL HYPOXIA; CELL MIGRATION; CONTROLLED STUDY; DISEASE ACTIVITY; ENZYME INDUCTION; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOREACTIVITY; IN VITRO STUDY; MAJOR CLINICAL STUDY; METASTASIS; MOUSE; NONHUMAN; OVARY CANCER; PRACTICE GUIDELINE; PROTEIN DEPLETION; PROTEIN EXPRESSION; SURVIVAL RATE; SURVIVAL TIME; TRANSCRIPTION INITIATION; TUMOR DIFFERENTIATION; ANIMAL; CANCER TRANSPLANTATION; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MIDDLE AGED; NEOPLASM; NUDE MOUSE; OVARY TUMOR; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE; TUMOR INVASION;

ADULT; AGED; ANIMALS; CADHERINS; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MICE; MICE, NUDE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM TRANSPLANTATION; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PROTEIN-LYSINE 6-OXIDASE; REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION;

EID: 84907284701     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2014.3448     Document Type: Article

References (44)

1. Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin 63: 11-30, 2013.
2. Thibault B, Castells M, Delord JP and Couderc B: Ovarian cancer microenvironment: implications for cancer dissemination and chemoresistance acquisition. Cancer Metastasis Rev: Dec 20, 2013 (Epub ahead of print).
3. Ozols RF, Bundy BN, Greer BE, et al: Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 21: 3194-3200, 2003.
4. Garcia AA, Hirte H, Fleming G, et al: Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia. J Clin Oncol 26: 76-82, 2008.
5. Penson RT, Dizon DS, Cannistra SA, et al: Phase II study of carboplatin, paclitaxel, and bevacizumab with maintenance bevacizumab as first-line chemotherapy for advanced mullerian tumors. J Clin Oncol 28: 154-159, 2010.
6. Berkenblit A, Seiden MV, Matulonis UA, et al: A phase II trial of weekly docetaxel in patients with platinum-resistant epithelial ovarian, primary peritoneal serous cancer, or fallopian tube cancer. Gynecol Oncol 95: 624-631, 2004.
7. Agarwal R and Kaye SB: Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat Rev Cancer 3: 502-516, 2003.
8. Cannistra SA: Cancer of the ovary. N Engl J Med 351: 2519-2529, 2004.
9. Hennessy BT, Coleman RL and Markman M: Ovarian cancer. Lancet 374: 1371-1382, 2009.
10. Joyce JA and Pollard JW: Microenvironmental regulation of metastasis. Nat Rev Cancer 9: 239-252, 2009.
11. Vaupel P, Kallinowski F and Okunieff P: Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer Res 49: 6449-6465, 1989.
12. Anderson AR, Weaver AM, Cummings PT and Quaranta V: Tumor morphology and phenotypic evolution driven by selective pressure from the microenvironment. Cell 127: 905-915, 2006.
13. Rademakers SE, Span PN, Kaanders JH, Sweep FC, van der Kogel AJ and Bussink J: Molecular aspects of tumour hypoxia. Mol Oncol 2: 41-53, 2008.
14. Chan DA, Sutphin PD, Yen SE and Giaccia AJ: Coordinate regulation of the oxygen-dependent degradation domains of hypoxia-inducible factor 1α. Mol Cell Biol 25: 6415-6426, 2005.
15. Ratcliffe PJ, O'Rourke JF, Maxwell PH and Pugh CW: Oxygen sensing, hypoxia-inducible factor-1 and the regulation of mammalian gene expression. J Exp Biol 201: 1153-1162, 1998.
16. Semenza GL: Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics. Oncogene 29: 625-634, 2010.
17. Bell EL, Klimova TA, Eisenbart J, et al: The Qo site of the mitochondrial complex III is required for the transduction of hypoxic signaling via reactive oxygen species production. J Cell Biol 177: 1029-1036, 2007.
18. 2sensing. J Biol Chem 275: 25130-25138, 2000.
19. Callapina M, Zhou J, Schmid T, Köhl R and Brüne B: NO restores HIF-1α hydroxylation during hypoxia: role of reactive oxygen species. Free Radic Biol Med 39: 925-936, 2005.
20. Erler JT, Bennewith KL, Nicolau M, et al: Lysyl oxidase is essential for hypoxia-induced metastasis. Nature 440: 1222-1226, 2006.
21. Stewart GD, Gray K, Pennington CJ, et al: Analysis of hypoxiaassociated gene expression in prostate cancer: lysyl oxidase and glucose transporter-1 expression correlate with Gleason score. Oncol Rep 20: 1561-1567, 2008.
22. Schietke R, Warnecke C, Wacker I, et al: The lysyl oxidases LOX and LOXL2 are necessary and sufficient to repress E-cadherin in hypoxia: insights into cellular transformation processes mediated by HIF-1. J Biol Chem 285: 6658-6669, 2010.
23. Pez F, Dayan F, Durivault J, et al: The HIF-1-inducible lysyl oxidase activates HIF-1 via the Akt pathway in a positive regulation loop and synergizes with HIF-1 in promoting tumor cell growth. Cancer Res 71: 1647-1657, 2011.
24. Ji F, Wang Y, Qiu L, et al: Hypoxia inducible factor 1α-mediated LOX expression correlates with migration and invasion in epithelial ovarian cancer. Int J Oncol 42: 1578-1588, 2013.
25. Wang V, Davis DA, Haque M, Huang LE and Yarchoan R: Differential gene up-regulation by hypoxia-inducible factor-1α and hypoxia-inducible factor-2α in HEK293T cells. Cancer Res 65: 3299-3306, 2005.
26. Elvidge GP, Glenny L, Appelhoff RJ, Ratcliffe PJ, Ragoussis J and Gleadle JM: Concordant regulation of gene expression by hypoxia and 2-oxoglutarate-dependent dioxygenase inhibition: the role of HIF-1α, HIF-2α, and other pathways. J Biol Chem 281: 15215-15226, 2006.
27. Warnecke C, Weidemann A, Volke M, et al: The specific contribution of hypoxia-inducible factor-2α to hypoxic gene expression in vitro is limited and modulated by cell type-specific and exogenous factors. Exp Cell Res 314: 2016-2027, 2008.
28. Kagan HM and Li W: Lysyl oxidase: properties, specificity, and biological roles inside and outside of the cell. J Cell Biochem 88: 660-672, 2003.
29. Payne SL, Hendrix MJ and Kirschmann DA: Paradoxical roles for lysyl oxidases in cancer-A prospect. J Cell Biochem 101: 1338-1354, 2007.
30. Polgar N, Fogelgren B, Shipley JM and Csiszar K: Lysyl oxidase interacts with hormone placental lactogen and synergistically promotes breast epithelial cell proliferation and migration. J Biol Chem 282: 3262-3272, 2007.
31. Sullivan R and Graham CH: Hypoxia-driven selection of the metastatic phenotype. Cancer Metastasis Rev 26: 319-331, 2007.
32. Axelson H, Fredlund E, Ovenberger M, Landberg G and Påhlman S: Hypoxia-induced dedifferentiation of tumor cells-A mechanism behind heterogeneity and aggressiveness of solid tumors. Semin Cell Dev Biol 16: 554-563, 2005.
33. Hanahan D and Weinberg RA: Hallmarks of cancer: the next generation. Cell 144: 646-674, 2011.
34. Imai T, Horiuchi A, Wang C, et al: Hypoxia attenuates the expression of E-cadherin via up-regulation of SNAIL in ovarian carcinoma cells. Am J Pathol 163: 1437-1447, 2003.
35. Esteban MA, Tran MG, Harten SK, et al: Regulation of E-cadherin expression by VHL and hypoxia-inducible factor. Cancer Res 66: 3567-3575, 2006.
36. Krishnamachary B, Zagzag D, Nagasawa H, et al: Hypoxiainducible factor-1-dependent repression of E-cadherin in von Hippel-Lindau tumor suppressor-null renal cell carcinoma mediated by TCF3, ZFHX1A, and ZFHX1B. Cancer Res 66: 2725-2731, 2006.
37. Peinado H, Del Carmen Iglesias-de la Cruz M, Olmeda D, et al: A molecular role for lysyl oxidase-like 2 enzyme in snail regulation and tumor progression. EMBO J 24: 3446-3458, 2005.
38. Peng HL, He L and Zhao X: Association of reduced immunohistochemical expression of E-cadherin with a poor ovarian cancer prognosis-results of a meta-Analysis. Asian Pac J Cancer Prev 13: 2003-2007, 2012.
39. Cai J, Niu X, Chen Y, et al: Emodin-induced generation of reactive oxygen species inhibits RhoA activation to sensitize gastric carcinoma cells to anoikis. Neoplasia 10: 41-51, 2008.
40. Dinh P, Harnett P, Piccart-Gebhart MJ and Awada A: New therapies for ovarian cancer: cytotoxics and molecularly targeted agents. Crit Rev Oncol Hematol 67: 103-112, 2008.
41. Galanis A, Pappa A, Giannakakis A, Lanitis E, Dangaj D and Sandaltzopoulos R: Reactive oxygen species and HIF-1 signalling in cancer. Cancer Lett 266: 12-20, 2008.
42. Kirschmann DA, Seftor EA, Fong SF, et al: A molecular role for lysyl oxidase in breast cancer invasion. Cancer Res 62: 4478-4483, 2002.
43. 2activates pro-matrix metalloproteinase-2 through receptor tyrosine kinases/phosphatidylinositol 3-kinase/NF-κB pathway. J Biol Chem 277: 30271-30282, 2002.
44. Woznick AR, Braddock AL, Dulai M, et al: Lysyl oxidase expression in bronchogenic carcinoma. Am J Surg 189: 297-301, 2005.